For informational purposes only — not investment advice

← Back to signals

CMPS

Compass, Inc.

Research: Finviz ↗·Perplexity ↗

No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.

Days to cover (short int.)
7.7d↑+1.0%
as of 2026-10-30 · shares short vs 2026-09-30

News Summary

Positive

CMPS (Compass Pathways) beat Q3 loss estimates and confirmed COMP360 psilocybin therapy on track for H1 2027 launch, but competitive pressure from Usona Institute's FDA filing briefly rattled the stock; analyst sentiment improved from 'strong sell' to 'hold'/'buy' by mid-November despite mixed price targets ($10–$65 range). COMP (Compass, Inc. real estate) delivered record Q3 results with $3.9B revenue (+11.6% YoY), $306M adjusted EBITDA, and strong free cash flow ($240M), significantly outperforming a down housing market.

Red flags

  • •CMPS: Significant analyst price-target divergence ($10–$65 range) suggests high uncertainty around COMP360 commercialization prospects
  • •CMPS: Competitive psilocybin therapy filing by Usona Institute triggered sector selloff and 'worst day in months' volatility
  • •CMPS: Rolling NDA submission timeline ('within two weeks' as of Nov 3) is aggressive and execution-dependent for H1 2027 launch

Fund 13D/13G Filings (1)

Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).

FundForm∆ Shares% of ClassSince FilingFiledSrc
D1 CapitalSC 13GNEW6.1%
+7.8% vs SPY
+4.6% abs
2026-11-16↗